Clinical Research: Sub-Investigator
Protocol 206207-016-00. A 6-Month, Single-Masked, Multicenter, Randomized, Controlled Study to Assess the Safety and Efficacy of 700 ug Dexamethasone Posterior Segment Drug Delivery System Applicator System as Adjunctive Therapy to Lucentis® Compared with Lucentis® Alone in the Treatment of Patients with Choroidal Neovascularization Secondary to Age-Related Macular Degeneration. Sub-Investigator. September 2007. Sponsor: Allergan.
Protocol VGFT-OD-0605: A Randomized, Double Masked, Active Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects with Neovascular Age-Related Macular Degeneration. Sub-investigator. July 2007. Sponsor: Regeneron.
CNV Secondary to AMD Treated with BEta RadiatioN Epiretinal Therapy (CABERNET). A Randomized, Prospective, Active Controlled, Study of the Epi-Rad90™ Ophthalmic System for the Treatment of Subfoveal Choroidal Neovascularization Associated with Wet Age-Related Macular Degeneration. Sub-investigator. July 2007. Sponsor: Neovista.
Molecular Prognostic Testing for Eye Melanoma. Validation of a Molecular Test for Predicting Metastasis in Patients with Uveal Melanoma. Multicenter, prospective study designed to analyze uveal melanomas and suspicious uveal nevi for gene expression profiles that predict metastatic risk. Sub-investigator. January 2007.
OPHTEC Model 311 Artificial Iris Lens For the Treatment of Visual Disturbances Resulting From Partial or Total Absence of the Human Iris. Continued Access Compassionate Use Study. Sub-investigator. March 2007.
AMD DOC Study. Detection of Onset of New Choroidal Using Preferential Hyperacuity Perimeter. Sub-investigator. March 2007.
VERTACL Study. Multi-center study investigating the use of Verteporfin and Triamcinolone Acetonide for AMD. Sub-investigator. January 2007.
